Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
New England Journal of Medicine, 2020 BACKGROUND Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Yi-long Wu +23 more
semanticscholar +1 more source
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Cancers, 2021 Simple Summary Growth factors are hormone-like molecules able to promote division and migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor growth and metastasis. Here we review the epidermal growth factor (EGF), which
M. L. Uribe, Ilaria Marrocco, Y. Yarden
semanticscholar +1 more source
WASH and Tsg101/ALIX-dependent diversion of stress-internalized EGFR from the canonical endocytic pathway [PDF]
, 2015 Stress exposure triggers ligand-independent EGF receptor (EGFR) endocytosis, but its post-endocytic fate and role in regulating signalling are unclear. We show that the p38 MAP kinase-dependent, EGFR tyrosine kinase (TK)-independent EGFR internalization ...
Burgoyne, T +6 more
core +1 more source
UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells
OncoImmunology, 2020 Induction or selection of radioresistant cancer (stem) cells following standard radiotherapy is presumably one of the major causes for recurrence of metastatic disease.
Claudia Arndt +21 more
doaj +1 more source
Decreasing Abdominal Circumference Is Associated with Improving Estimated Glomerular Filtration Rate (eGFR) with Lifestyle Modification in Japanese Men: A Pilot Study [PDF]
, 2011 The link between changes in a subject's metabolic syndrome components and his estimated glomerular filtration rate (eGFR) was evaluated in healthy Japanese men. We used data from 120 Japanese men (45.5±8.4 years) with a 1-year follow up. eGFR was defined
Makino, Hirofumi +3 more
core +1 more source
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
New England Journal of Medicine, 2019 BACKGROUND Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.
S. Ramalingam +23 more
semanticscholar +1 more source
Journal for ImmunoTherapy of Cancer, 2022 Backgrounds Immunotherapy is less effective in patients with epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC). Lower programmed cell death-ligand 1 (PD-L1) expression and tumor mutation burden (TMB) are reported to be the
Lei Yang +12 more
semanticscholar +1 more source
Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. [PDF]
, 2015 We hypothesized that aberrations activating epidermal growth factor receptor (EGFR) via dimerization would be more sensitive to anti-dimerization agents (e.g., cetuximab).
Bazhenova, Lyudmila +6 more
core +3 more sources
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. [PDF]
, 2019 Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance.
A Hübner +66 more
core +1 more source